Welcome to our dedicated page for Zimmer Biomet SEC filings (Ticker: ZBH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Zimmer Biomet Holdings, Inc. filings document a public medical technology company with common stock listed under ZBH and several registered notes listed on the New York Stock Exchange. Recent 8-K reports cover quarterly and annual operating results, updated financial guidance, executive officer departures and interim finance leadership, debt securities, and completed acquisition activity.
The company's proxy and event filings disclose board and executive compensation matters, governance votes, Section 12(b) securities, material agreements, senior unsecured debt obligations, and exhibits tied to earnings releases. These records frame Zimmer Biomet's capital structure, leadership changes, shareholder governance and financial reporting for its orthopedic and musculoskeletal technology business.
Jafry Syed A. reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings, Inc. director Syed A. Jafry reported compensation-related equity awards. He received 1,517.274 Restricted Stock Units tied to common stock and 875.350 Phantom Stock Units, each representing a 1-for-1 right to receive one share of common stock.
The Restricted Stock Units are immediately 100% vested but are subject to mandatory deferral until the later of the end of his board service or three years after the grant date. The Phantom Stock Units were accrued under the company’s Deferred Compensation Plan for Non-Employee Directors and will be settled in shares within sixty days after he ceases to serve as a director.
Zimmer Biomet director Arthur J. Higgins received new equity-based compensation awards. He was granted 1,517.274 Restricted Stock Units tied to common stock, bringing his Restricted Stock Unit holdings to 26,382 units. He also received 875.350 Phantom Stock Units under the Deferred Compensation Plan, increasing his phantom unit balance to 37,357.322 units.
The phantom units have a 1-for-1 conversion ratio into common stock and are to be settled in shares within sixty days after he ceases serving as a director. The Restricted Stock Units are immediately 100% vested but are subject to mandatory deferral until the later of his termination of service as a director or three years after the grant date, and include prior-year grants with different deferral periods.
HAGEMANN ROBERT reported acquisition or exercise transactions in this Form 4 filing.
Zimmer Biomet Holdings director Robert Hagemann received equity-based compensation rather than buying shares on the market. On May 22, 2026, he was granted 1,517.274 Restricted Stock Units, all immediately vested but subject to mandatory deferral until at least three years after the grant or his board service ends.
He was also credited with 875.350 Phantom Stock Units under the company’s Deferred Compensation Plan for Non-Employee Directors, bringing his phantom unit balance to 32,952.074 units. These phantom units track common stock 1-for-1 and will be settled in shares within sixty days after he ceases serving as a director. Following the RSU grant, he holds 25,927 Restricted Stock Units in total, including prior awards with different deferral periods.
Suketu Upadhyay filed a Form 144 disclosing a proposed sale of 31,253 shares of common stock of ZBH, with a reported aggregate value of $2,608,859.38 for a sale dated 05/12/2026. The filing lists prior issuer grants and vesting events dated 07/01/2020, 06/30/2021, and 02/21/2023.
Zimmer Biomet Holdings Inc. ownership disclosure: T. Rowe Price Associates, Inc. reports beneficial ownership of 7,997,806 shares of Common Stock, representing 4.1% of the class as shown in the amendment. The filing lists 7,523,342 shares with sole voting power and 7,997,806 shares with sole dispositive power.
The cover shows 03/31/2026 and the filing is signed on 05/15/2026.
ZBH notice lists proposed sales of Common Stock originating from employee plans and restricted‑stock vesting recorded through 05/12/2026. The entries show multiple ESPP purchases and restricted stock vesting events with per‑event share counts (examples: 13,467 on 02/18/2025, 8,851 on 11/10/2024), and identify Fidelity Brokerage Services LLC as the broker record.
Zimmer Biomet Holdings, Inc. plans to repurchase up to $1.0 billion of its common stock during fiscal year 2026. This reflects a $250 million increase from its prior capital allocation assumption for 2026 and will be executed under an existing $1.5 billion share repurchase authorization approved in February 2026.
The company may buy shares in the open market and/or through structured repurchase agreements with third parties, with timing and actual amounts influenced by market conditions, stock price, capital availability and alternative uses of capital.
Stellato Paul A reported acquisition or exercise transactions in this Form 4 filing.
ZIMMER BIOMET HOLDINGS, INC. reported that VP, Controller and Chief Accounting Officer Paul A. Stellato received a grant of 9,232 Restricted Stock Units on May 1, 2026. Each unit represents a contingent right to receive one share of the company’s common stock.
The award vests annually over three years in equal one‑third installments, beginning on May 1, 2027. Following this grant, Stellato holds 9,232 Restricted Stock Units directly, reflecting a routine equity-based compensation award rather than an open-market stock purchase or sale.
Zimmer Biomet reported stronger results for the quarter ended March 31, 2026. Net sales rose to $2,086.7M, up 9.3% from $1,909.1M a year earlier, driven by the Paragon 28 acquisition, foreign currency tailwinds, customer stocking, ROSA robots, and new products.
Net earnings attributable to Zimmer Biomet increased to $238.1M from $182.0M, with diluted EPS rising to $1.22 from $0.91. Knees, Hips, S.E.T., and Technology & Data, Bone Cement and Surgical all grew, with S.E.T. up 19.5%.
Operating profit improved to $373.2M, supported by a roughly $30M benefit from probable U.S. tariff refunds, lower restructuring charges, reduced R&D spending, and restructuring savings. For 2026, the company expects net sales growth of 2.5%–4.5%, including contributions from Paragon 28 and modestly positive foreign exchange.
Zimmer Biomet Holdings Inc reports a Schedule 13G filing showing 14,767,527 common shares beneficially owned. The filing states this represents 7.54% of the class and that Vanguard Capital Management has sole dispositive power over 14,767,527 shares and sole voting power for 1,974,115 shares. The filing is signed on 04/30/2026.